Strengthening Licensing Valuation: Crafting a Winning Case through a Triangulated Methodology

In the high-stakes environment of pharmaceutical licensing, winning a successful bid requires a valuation that is both aggressive and defensible. While our recent case study focused on Drug X,a blinded Phase 2 KRAS inhibitor. Omnitheia’s strategic framework, is designed to provide a comprehensive valuation for assets across the entire clinical pipeline. This triangulated approach empowers…

Optimising the Target Product Profile (TPP) through Real-World Evidence

For any clinical candidate, the Target Product Profile (TPP) serves as the blueprint for its commercial future. However, many profiles are hampered by fragmented, generic, or historical data that fails to reflect today’s market reality. Omnitheia optimizes the TPP by infusing it with Real-World Evidence (RWE) to validate both its clinical and commercial potential. Building…

The Omnitheia Confidence Score: Eliminating Risk in Professional Analytics